Forskning ved Københavns Universitet - Københavns Universitet

Forside

Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. / Zhang, Qian; Raghunath, Puthryaveett N; Xue, Liquan; Majewski, Miroslaw; Carpentieri, David F; Odum, Niels; Morris, Stephan; Skorski, Tomasz; Wasik, Mariusz A.

I: Journal of Immunology, Bind 168, Nr. 1, 2002, s. 466-74.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Zhang, Q, Raghunath, PN, Xue, L, Majewski, M, Carpentieri, DF, Odum, N, Morris, S, Skorski, T & Wasik, MA 2002, 'Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma', Journal of Immunology, bind 168, nr. 1, s. 466-74. <http://www.jimmunol.org/cgi/content/abstract/168/1/466>

APA

Zhang, Q., Raghunath, P. N., Xue, L., Majewski, M., Carpentieri, D. F., Odum, N., Morris, S., Skorski, T., & Wasik, M. A. (2002). Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. Journal of Immunology, 168(1), 466-74. http://www.jimmunol.org/cgi/content/abstract/168/1/466

Vancouver

Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N o.a. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. Journal of Immunology. 2002;168(1):466-74.

Author

Zhang, Qian ; Raghunath, Puthryaveett N ; Xue, Liquan ; Majewski, Miroslaw ; Carpentieri, David F ; Odum, Niels ; Morris, Stephan ; Skorski, Tomasz ; Wasik, Mariusz A. / Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. I: Journal of Immunology. 2002 ; Bind 168, Nr. 1. s. 466-74.

Bibtex

@article{9e58d780fd0111ddb219000ea68e967b,
title = "Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma",
abstract = "Accumulating evidence indicates that expression of anaplastic lymphoma kinase (ALK), typically due to t(2;5) translocation, defines a distinct type of T/null-cell lymphoma (TCL). The resulting nucleophosmin (NPM) /ALK chimeric kinase is constitutively active and oncogenic. Downstream effector molecules triggered by NPM/ALK remain, however, largely unidentified. Here we report that NPM/ALK induces continuous activation of STAT3. STAT3 displayed tyrosine phosphorylation and DNA binding in all (four of four) ALK+ TCL cell lines tested. The activation of STAT3 was selective because none of the other known STATs was consistently tyrosine phosphorylated in these cell lines. In addition, malignant cells in tissue sections from all (10 of 10) ALK+ TCL patients expressed tyrosine-phosphorylated STAT3. Transfection of BaF3 cells with NPM/ALK resulted in tyrosine phosphorylation of STAT3. Furthermore, STAT3 was constitutively associated with NPM/ALK in the ALK+ TCL cell lines. Additional studies into the mechanisms of STAT3 activation revealed that the ALK+ TCL cells expressed a positive regulator of STAT3 activation, protein phosphatase 2A (PP2A), which was constitutively associated with STAT3. Treatment with the PP2A inhibitor calyculin A abrogated tyrosine phosphorylation of STAT3. Finally, ALK+ T cells failed to express a negative regulator of activated STAT3, protein inhibitor of activated STAT3. These data indicate that NPM/ALK activates STAT3 and that PP2A and lack of protein inhibitor of activated STAT3 may be important in maintaining STAT3 in the activated state in the ALK+ TCL cells. These results also suggest that activated STAT3, which is known to display oncogenic properties, as well as its regulatory molecules may represent attractive targets for novel therapies in ALK+ TCL.",
author = "Qian Zhang and Raghunath, {Puthryaveett N} and Liquan Xue and Miroslaw Majewski and Carpentieri, {David F} and Niels Odum and Stephan Morris and Tomasz Skorski and Wasik, {Mariusz A}",
note = "Keywords: Carrier Proteins; Cell Line; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lymphoma, T-Cell; Models, Biological; Phosphoprotein Phosphatases; Phosphorylation; Phosphotyrosine; Protein Phosphatase 2; Protein-Tyrosine Kinases; RNA, Neoplasm; STAT3 Transcription Factor; Trans-Activators; Transfection; Tumor Cells, Cultured; Up-Regulation",
year = "2002",
language = "English",
volume = "168",
pages = "466--74",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

RIS

TY - JOUR

T1 - Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma

AU - Zhang, Qian

AU - Raghunath, Puthryaveett N

AU - Xue, Liquan

AU - Majewski, Miroslaw

AU - Carpentieri, David F

AU - Odum, Niels

AU - Morris, Stephan

AU - Skorski, Tomasz

AU - Wasik, Mariusz A

N1 - Keywords: Carrier Proteins; Cell Line; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lymphoma, T-Cell; Models, Biological; Phosphoprotein Phosphatases; Phosphorylation; Phosphotyrosine; Protein Phosphatase 2; Protein-Tyrosine Kinases; RNA, Neoplasm; STAT3 Transcription Factor; Trans-Activators; Transfection; Tumor Cells, Cultured; Up-Regulation

PY - 2002

Y1 - 2002

N2 - Accumulating evidence indicates that expression of anaplastic lymphoma kinase (ALK), typically due to t(2;5) translocation, defines a distinct type of T/null-cell lymphoma (TCL). The resulting nucleophosmin (NPM) /ALK chimeric kinase is constitutively active and oncogenic. Downstream effector molecules triggered by NPM/ALK remain, however, largely unidentified. Here we report that NPM/ALK induces continuous activation of STAT3. STAT3 displayed tyrosine phosphorylation and DNA binding in all (four of four) ALK+ TCL cell lines tested. The activation of STAT3 was selective because none of the other known STATs was consistently tyrosine phosphorylated in these cell lines. In addition, malignant cells in tissue sections from all (10 of 10) ALK+ TCL patients expressed tyrosine-phosphorylated STAT3. Transfection of BaF3 cells with NPM/ALK resulted in tyrosine phosphorylation of STAT3. Furthermore, STAT3 was constitutively associated with NPM/ALK in the ALK+ TCL cell lines. Additional studies into the mechanisms of STAT3 activation revealed that the ALK+ TCL cells expressed a positive regulator of STAT3 activation, protein phosphatase 2A (PP2A), which was constitutively associated with STAT3. Treatment with the PP2A inhibitor calyculin A abrogated tyrosine phosphorylation of STAT3. Finally, ALK+ T cells failed to express a negative regulator of activated STAT3, protein inhibitor of activated STAT3. These data indicate that NPM/ALK activates STAT3 and that PP2A and lack of protein inhibitor of activated STAT3 may be important in maintaining STAT3 in the activated state in the ALK+ TCL cells. These results also suggest that activated STAT3, which is known to display oncogenic properties, as well as its regulatory molecules may represent attractive targets for novel therapies in ALK+ TCL.

AB - Accumulating evidence indicates that expression of anaplastic lymphoma kinase (ALK), typically due to t(2;5) translocation, defines a distinct type of T/null-cell lymphoma (TCL). The resulting nucleophosmin (NPM) /ALK chimeric kinase is constitutively active and oncogenic. Downstream effector molecules triggered by NPM/ALK remain, however, largely unidentified. Here we report that NPM/ALK induces continuous activation of STAT3. STAT3 displayed tyrosine phosphorylation and DNA binding in all (four of four) ALK+ TCL cell lines tested. The activation of STAT3 was selective because none of the other known STATs was consistently tyrosine phosphorylated in these cell lines. In addition, malignant cells in tissue sections from all (10 of 10) ALK+ TCL patients expressed tyrosine-phosphorylated STAT3. Transfection of BaF3 cells with NPM/ALK resulted in tyrosine phosphorylation of STAT3. Furthermore, STAT3 was constitutively associated with NPM/ALK in the ALK+ TCL cell lines. Additional studies into the mechanisms of STAT3 activation revealed that the ALK+ TCL cells expressed a positive regulator of STAT3 activation, protein phosphatase 2A (PP2A), which was constitutively associated with STAT3. Treatment with the PP2A inhibitor calyculin A abrogated tyrosine phosphorylation of STAT3. Finally, ALK+ T cells failed to express a negative regulator of activated STAT3, protein inhibitor of activated STAT3. These data indicate that NPM/ALK activates STAT3 and that PP2A and lack of protein inhibitor of activated STAT3 may be important in maintaining STAT3 in the activated state in the ALK+ TCL cells. These results also suggest that activated STAT3, which is known to display oncogenic properties, as well as its regulatory molecules may represent attractive targets for novel therapies in ALK+ TCL.

M3 - Journal article

C2 - 11751994

VL - 168

SP - 466

EP - 474

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -

ID: 10617116